Cargando…

Suppression of tumour growth by orally administered osteopontin is accompanied by alterations in tumour blood vessels

BACKGROUND: The integrin-binding protein osteopontin is strongly associated with tumour development, yet is an abundant dietary component as a constituent of human and bovine milk. Therefore, we tested the effect of orally administered osteopontin (o-OPN) on the development of subcutaneous tumours i...

Descripción completa

Detalles Bibliográficos
Autores principales: Rittling, S R, Wejse, P L, Yagiz, K, Warot, G A, Hui, T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3950862/
https://www.ncbi.nlm.nih.gov/pubmed/24473400
http://dx.doi.org/10.1038/bjc.2014.10
_version_ 1782307064030167040
author Rittling, S R
Wejse, P L
Yagiz, K
Warot, G A
Hui, T
author_facet Rittling, S R
Wejse, P L
Yagiz, K
Warot, G A
Hui, T
author_sort Rittling, S R
collection PubMed
description BACKGROUND: The integrin-binding protein osteopontin is strongly associated with tumour development, yet is an abundant dietary component as a constituent of human and bovine milk. Therefore, we tested the effect of orally administered osteopontin (o-OPN) on the development of subcutaneous tumours in mice. METHODS: Bovine milk osteopontin was administered in drinking water to tumour-bearing immune-competent mice. Tumour growth, proliferation, necrosis, apoptosis and blood vessel size and number were measured. Expression of the α(9) integrin was determined. RESULTS: o-OPN suppressed tumour growth, increased the extent of necrosis, and induced formation of abnormally large blood vessels. Anti-OPN reactivity detected in the plasma of OPN-null mice fed OPN suggested that tumour-blocking peptides were absorbed during digestion, but the o-OPN effect was likely distinct from that of an RGD peptide. Expression of the α(9) integrin was detected on both tumour cells and blood vessels. Potential active peptides from the α(9) binding site of OPN were identified by mass spectrometry following in vitro digestion, and injection of these peptides suppressed tumour growth. CONCLUSIONS: These results suggest that peptides derived from o-OPN are absorbed and interfere with tumour growth and normal vessel development. o-OPN-derived peptides that target the α(9) integrin are likely involved.
format Online
Article
Text
id pubmed-3950862
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-39508622015-03-04 Suppression of tumour growth by orally administered osteopontin is accompanied by alterations in tumour blood vessels Rittling, S R Wejse, P L Yagiz, K Warot, G A Hui, T Br J Cancer Molecular Diagnostics BACKGROUND: The integrin-binding protein osteopontin is strongly associated with tumour development, yet is an abundant dietary component as a constituent of human and bovine milk. Therefore, we tested the effect of orally administered osteopontin (o-OPN) on the development of subcutaneous tumours in mice. METHODS: Bovine milk osteopontin was administered in drinking water to tumour-bearing immune-competent mice. Tumour growth, proliferation, necrosis, apoptosis and blood vessel size and number were measured. Expression of the α(9) integrin was determined. RESULTS: o-OPN suppressed tumour growth, increased the extent of necrosis, and induced formation of abnormally large blood vessels. Anti-OPN reactivity detected in the plasma of OPN-null mice fed OPN suggested that tumour-blocking peptides were absorbed during digestion, but the o-OPN effect was likely distinct from that of an RGD peptide. Expression of the α(9) integrin was detected on both tumour cells and blood vessels. Potential active peptides from the α(9) binding site of OPN were identified by mass spectrometry following in vitro digestion, and injection of these peptides suppressed tumour growth. CONCLUSIONS: These results suggest that peptides derived from o-OPN are absorbed and interfere with tumour growth and normal vessel development. o-OPN-derived peptides that target the α(9) integrin are likely involved. Nature Publishing Group 2014-03-04 2014-01-28 /pmc/articles/PMC3950862/ /pubmed/24473400 http://dx.doi.org/10.1038/bjc.2014.10 Text en Copyright © 2014 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Molecular Diagnostics
Rittling, S R
Wejse, P L
Yagiz, K
Warot, G A
Hui, T
Suppression of tumour growth by orally administered osteopontin is accompanied by alterations in tumour blood vessels
title Suppression of tumour growth by orally administered osteopontin is accompanied by alterations in tumour blood vessels
title_full Suppression of tumour growth by orally administered osteopontin is accompanied by alterations in tumour blood vessels
title_fullStr Suppression of tumour growth by orally administered osteopontin is accompanied by alterations in tumour blood vessels
title_full_unstemmed Suppression of tumour growth by orally administered osteopontin is accompanied by alterations in tumour blood vessels
title_short Suppression of tumour growth by orally administered osteopontin is accompanied by alterations in tumour blood vessels
title_sort suppression of tumour growth by orally administered osteopontin is accompanied by alterations in tumour blood vessels
topic Molecular Diagnostics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3950862/
https://www.ncbi.nlm.nih.gov/pubmed/24473400
http://dx.doi.org/10.1038/bjc.2014.10
work_keys_str_mv AT rittlingsr suppressionoftumourgrowthbyorallyadministeredosteopontinisaccompaniedbyalterationsintumourbloodvessels
AT wejsepl suppressionoftumourgrowthbyorallyadministeredosteopontinisaccompaniedbyalterationsintumourbloodvessels
AT yagizk suppressionoftumourgrowthbyorallyadministeredosteopontinisaccompaniedbyalterationsintumourbloodvessels
AT warotga suppressionoftumourgrowthbyorallyadministeredosteopontinisaccompaniedbyalterationsintumourbloodvessels
AT huit suppressionoftumourgrowthbyorallyadministeredosteopontinisaccompaniedbyalterationsintumourbloodvessels